NDAORALCAPSULE
Approved
Jun 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
MECLOMEN (meclofenamate sodium) by Pfizer is clinical pharmacology pharmacodynamics meclofenamate sodium is a nonsteroidal agent which has demonstrated anti-inflammatory, analgesic, and antipyretic activity in laboratory animals. Approved for idiopathic heavy menstrual blood loss (see, rheumatoid arthritis. First approved in 1980.
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MECLOMEN (meclofenamate sodium) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis and 5-lipoxygenase activity. It is indicated for rheumatoid arthritis and idiopathic heavy menstrual blood loss. The drug provides anti-inflammatory, analgesic, and antipyretic effects with a rapid onset and short half-life of 0.8–2.1 hours.
LOE Approaching
This product is approaching loss of exclusivity with minimal commercial investment, indicating a declining team footprint and transition toward generic competition.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Meclofenamate sodium is a nonsteroidal agent which has demonstrated anti-inflammatory, analgesic, and antipyretic activity in laboratory animals. The mode of action, like that of other nonsteroidal anti-inflammatory agents, is not known. Therapeutic action…
Worked on MECLOMEN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.